RESEARCH ARTICLE

REVISED Functional proteomic profiling reveals KLK13 and TMPRSS11D as active proteases in the lower female reproductive tract [version 2; peer review: 2 approved]

Carla M.J. Muytjens^{1,2}, Yijing Yu^{1,2}, Eleftherios P. Diamandis ¹⁻³

¹Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada

²Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Toronto, Canada

³Department of Clinical Biochemistry, University Health Network, Canada, Toronto, Canada

v2 First published: 19 Oct 2018, 7:1666
<https://doi.org/10.12688/f1000research.16255.1>

Latest published: 31 Dec 2018, 7:1666
<https://doi.org/10.12688/f1000research.16255.2>

Abstract

Background: Cervical-vaginal fluid (CVF) hydrates the mucosa of the lower female reproductive tract and is known to contain numerous proteases. The low pH of CVF (4.5 or below in healthy women of reproductive age) is a uniquely human attribute and poses a challenge for the proteolytic functioning of the proteases identified in this complex biological fluid. Despite the abundance of certain proteases in CVF, the proteolytic activity and function of proteases in CVF is not well characterized.

Methods: In the present study, we employed fluorogenic substrate screening to investigate the influence of pH and inhibitory compounds on the proteolytic activity in CVF. Activity-based probe (ABP) proteomics has evolved as a powerful tool to investigate active proteases within complex proteomes and a trypsin-specific ABP was used to identify active proteases in CVF.

Results: Serine proteases are among the most abundant proteins in the CVF proteome. Labeling human CVF samples with the trypsin-specific ABP revealed serine proteases transmembrane protein serine 11D and kallikrein-related peptidase 13 as active proteases in CVF. Furthermore, we demonstrated that the proteolytic activity in CVF is highly pH-dependent with an almost absolute inhibition of trypsin-like proteolytic activity at physiological pH levels.

Conclusions: These findings provide a framework to understand proteolytic activity in CVF. Furthermore, the present results provide clues for a novel regulatory mechanism in which fluctuations in CVF pH have the potential to control the catalytic activity in the lower female reproductive tract.

Keywords

cervical-vaginal fluid, serine proteases, activity-based probe proteomics

Open Peer Review

Approval Status

	1	2
version 2 (revision) 31 Dec 2018		 view
version 1 19 Oct 2018	 view	 view

1. **Georgios Pampalakis** , University of Patras, Patras, Greece

2. **Céline Deraison** , INSERM, Toulouse, France

Any reports and responses or comments on the article can be found at the end of the article.

Corresponding author: Eleftherios P. Diamandis (Eleftherios.diamandis@sinaihealthsystem.ca)

Author roles: **Muytjens CMJ:** Conceptualization, Data Curation, Formal Analysis, Investigation, Methodology, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; **Yu Y:** Data Curation, Formal Analysis, Investigation, Validation, Visualization, Writing – Review & Editing; **Diamandis EP:** Conceptualization, Project Administration, Supervision, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: The author(s) declared that no grants were involved in supporting this work.

Copyright: © 2018 Muytjens CMJ *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Muytjens CMJ, Yu Y and Diamandis EP. **Functional proteomic profiling reveals KLK13 and TMPRSS11D as active proteases in the lower female reproductive tract [version 2; peer review: 2 approved]** F1000Research 2018, 7:1666 <https://doi.org/10.12688/f1000research.16255.2>

First published: 19 Oct 2018, 7:1666 <https://doi.org/10.12688/f1000research.16255.1>

REVISED Amendments from Version 1

The following changes were made in the manuscript:

Methods:**Validation of KLK13 in CVF section**

We provided a reference for the production of the monoclonal KLK13 antibody used in this study.

Results:**Investigation of proteolytic activity in CVF section**

Figure 2: we have adjusted the wording in the legend to include the explanation of the relative trypsin-like activity.

Identification of active proteases TMPRSS11D and KLK13 section

Revised Figure 4 to highlight KLK13 and TMPRSS11D. We have adjusted the legend of the figure to reflect this change.

Validation of TMPRSS11D and KLK13 in CVF section

We have changed the wording in the manuscript from 225NRT to 225N.

Discussion:

We changed the following sentences in the discussion section: "This powerful approach resulted in the identification of serine proteases KLK13 and TMPRSS11D as major active proteolytic enzymes in CVF. ABP proteomics resulted in the identification of KLK13 and TMPRSS11D as active proteases in this complex biological fluid" as suggested by the reviewer.

We have included the appropriate reference to support the biological concentrations of KLKs in the CVF and the male reproductive system.

See referee reports

Introduction

Approximately 2–4% of the genes in the human genome account for proteases, and in addition, over 150 different protease inhibitors are encoded in the human genome¹. Proteases irreversibly modify proteins via peptide bond hydrolysis and thereby impact on both protein structure and function. As a result, proteases are implicated in nearly every significant biological process.

Cervical-vaginal fluid (CVF) hydrates the mucosa of the vagina and lower part of the cervix. Situated directly at the interface between the external environment and the internal milieu, CVF plays key roles in sexual intercourse, conception and provides a barrier against microbial invasion^{2–6}. Almost 8% of all proteins identified in CVF are proteases, which highlights the tremendous proteolytic potential of this complex biological fluid⁷. Interestingly, human CVF differs from other mammals in that it is uniquely acidic with levels of 4.5 or less in healthy women of reproductive age^{8,9}. The low pH is estrogen dependent and results from the conversion of glycogen to lactic acid by the vaginal microbiome or, alternatively, the vaginal lumen is acidified via active proton secretion across the vaginal epithelial membrane^{10–12}. The acidity levels in CVF pose a substantial challenge for protease activity in this environment. Despite the high abundance of proteases in CVF, their activity and functioning in the lower female reproductive tract remains to be elucidated.

Functional proteomics using an activity-based probe (ABP) coupled to mass spectrometry has emerged as a powerful tool

to study active proteases within complex proteomes^{13,14}. ABPs, designed to target certain classes of active proteases, have been successfully applied to investigate ABP-mediated profiling of complex proteomes, inhibitor screening and enzymatic target identification^{15,16}.

In the current study, ABP profiling of CVF resulted in the identification of transmembrane protein serine 11D (TMPRSS11D) and kallikrein-related peptidase 13 (KLK13) as active trypsin-like proteases. In addition, we observed a near complete cessation of trypsin-like proteolytic activity at physiological pH levels in CVF. Therefore, we propose a novel mechanism in which fluctuations in CVF pH have the potential to regulate the catalytic activity in the lower female reproductive tract. Understanding the protease activity and functioning in CVF can provide important insights in their mechanism of action and ultimately lead to novel protease targeted therapeutics.

Methods

Sample collection

CVF samples were collected from 10 healthy, non-pregnant female volunteers using a softcup collection device (Instead Inc. San Diego, CA) as described previously^{7,17}. Informed consent was obtained from all participants prior to sample collection. The collection and use of human samples was approved by the Research Ethic Board at Mount Sinai Hospital in Toronto (MSH REB 16-0137-E). All women abstained from sexual activity and douching at least 3 days prior to sample collection and had no self-reported vaginal infections. The sample was collected after 90 minutes via centrifugation (Eppendorf centrifuge, model 5415R) of the softcup inside a 50mL conical tube at 200xg for 2 minutes. CVF was transferred to a 1.5mL tube and centrifuged at 15,000xg for 20 minutes to remove cellular debris. Total protein of each CVF sample was determined using a Bradford protein assay (Thermo Fisher Scientific, #1856209). The samples were stored at -80°C until further use.

Estimation of protease abundance in CVF proteome

The estimation of protease abundance in the CVF proteome was based on the CVF proteome dataset from healthy non-pregnant women⁷. Proteases were identified by comparison with the Merops database and grouped according to their catalytic type¹. The log transformed MS1 area data were used as a proxy for the relative abundance of each protein within the dataset. CVF proteins and proteases were subsequently ranked according to the relative abundance and plots were produced using R (R version 3.5.0).

Investigation of proteolytic activity in CVF

The trypsin-like proteolytic activity in CVF was measured by incubating 0.1µg total protein CVF sample with 0.5mM of the fluorogenic t-butoxycarbonyl-tri-peptide-7-amino-4-methylcoumarin (AMC) synthetic peptide (Bachem, #4003460) with a valine (V), proline (P), arginine (R) tripeptide sequence. Fluorescence was measured every minute for 15 minutes on a Wallac Envision fluorometer (Perkin-Elmer) set at 355nm for excitation and 460nm for emission. All reactions were performed at 37°C in female reproductive tract buffer (20mM potassium phosphate, 60mM sodium chloride)¹⁸. To determine the influ-

ence of pH on the proteolytic activity in CVF the buffers were adjusted using NaOH and HCl so that pH ranged from 9.0 to 3.5 in 0.5 increments. Trypsin-like proteolytic activity in CVF was also measured in the presence of 1 mM phenylmethylsulfonyl fluoride (PMSF), 10mM ethylenediaminetetraacetic acid (EDTA) or 5nM soybean trypsin inhibitor (STI). Proteolytic activity was quantified by calculating the rate of substrate hydrolysis after subtraction of the fluorescence of enzyme-free reactions. All experiments were performed in triplicate on 2 separate days. Figures were prepared using **GraphPad Prism** (version 7.00 for Windows).

Visualization of trypsin-like proteolytic activity in CVF

A trypsin-specific, biotin-conjugated activity-based probe (ABP) was used to label the active enzymes in CVF specifically and covalently¹⁹. The probe was kindly provided by Professor Brendon Gilmore (Queen's University Belfast, Ireland). Active enzymes were labeled by incubating 1 µg total protein of CVF sample in 5 µL (in 10mM Tris, pH 8.0) with 1 µL 10x proteinase assay buffer (500mM Tris-HCl, pH8.0, 2% NP40, 15mM CaCl₂), 1 µL of 1 mM ABP and 2 µL H₂O. Additionally, CVF sample was incubated with 10mM EDTA, 1mM PMSF and 5nM STI prior to the labeling of the active enzymes with the ABP. After a 2-hour incubation at room temperature, the reaction was stopped using SDS sample buffer (31.25mM Tris-HCl pH 6.8, 12.5% glycerol, 1% SDS, 0.005% Bromphenol Blue (Biorad, #161-0747) containing 50mM DTT, followed by boiling for 10 minutes to denature the proteins. Samples were loaded on a 4–15% Mini-Protean TGX precast gel (Biorad, #456-1086/1083) and SDS gel electrophoresis was performed at 200V for approximately 30 minutes. Proteins were transferred using a 0.2 µm PVDF membrane (BioRad, #1704156) in a Trans-blot Turbo Blotting System (Biorad). The membranes were blocked with 5% casein in TBS-T (0.05% Tween-20 in 50mM Tris, 150 mM NaCl, pH 7.5) at room temperature for 2 hours, followed by a wash with TBS-T (3 × 10 minutes). The membrane was subsequently incubated with streptavidin-horseradish peroxidase (SA-HRP) (Jackson Immunoresearch, #016-030-084) in a 1:10,000 dilution in 1% casein in TBST-T for an hour, followed by an extensive wash with TBS-T (3 × 15 minutes, 3 × 5 minutes). A total of 125 µL of chemiluminescence substrate (GE healthcare, #45000875) was added per square centimeter of membrane. The membrane was then placed into an autoradiography cassette, exposed for 6 minutes and developed using x-ray film.

Separation of high and low molecular weight active trypsin-like proteases

CVF samples (N= 5) were fractionated using size exclusion chromatography (SEC) in order to isolate the fractions with demonstrated proteolytic activity. A total of 250µg total protein per sample was loaded onto a TSK gel G3000SW column (Tosoh Bioscience) in 0.1M Na₂HPO₄/Na₂SO₄ (pH 6.8) and fractionated with a constant flow rate of 0.5mL/min. Fractions were collected every minute throughout the gradient and subsequently analyzed for proteolytic activity using the fluorescent substrate and ABP as described previously. The trypsin-like proteolytic activity in the SEC fractions was quantified via comparison

to standard curve prepared with porcine trypsin (Sigma, 16,000 BAEE U/mg, #T0303).

Identification of active trypsin-like proteases in CVF via mass spectrometry

The fractionated CVF samples were prepared for gel electrophoresis by intermixing with SDS sample buffer followed by heating to 95°C in order to denature the proteins. Samples were loaded on a 4–15% Mini-Protean TGX precast gel (Biorad, #456-1086/1083) and SDS gel electrophoresis was performed at 200V. After completion of gel electrophoresis, the proteins in the gel were visualized using a Coomassie stain (Biorad, #1610787) and bands matching the protease-probe complexes were excised and prepared for mass spectrometry. The samples were concentrated with Omix C18MB tips (Agilent Technologies, #A5700310K) and eluted with 5µL buffer B (0.1% formic acid (FA), 65% acetonitrile (ACN)). To each eluted sample, 60µL of buffer A (0.1% FA, water) was added, of which 18 µL were loaded from a 96-well microplate autosampler onto a C18 trap column using the EASY-nLC1000 system (Thermo Fisher Scientific, #LC120) and running buffer C (0.1 % FA in water). The trap column consisted of IntegraFrit capillary (inner diameter 150 µm, New Objective, #IF15010xxxx) cut to 3.2 cm in length and packed in-house with 5µm Pursuit C-18 (Agilent Technologies). Peptides were eluted from the trap column at 300nL/min with an increasing concentration of buffer D (0.1% FA in ACN) over a 30-minute gradient onto a resolving 15 cm long PicoTip Emitter (75µm inner diameter, 8µm tip, New Objective) packed in-house with 3µm Pursuit C-18 (Agilent Technologies). The liquid chromatography setup was coupled online to a Q Exactive Plus (Thermo Fisher Scientific) mass spectrometer using a nanoelectrospray ionization source (Thermo Fisher Scientific) with capillary temperature set to 275°C and spray voltage of 2kV. A 60-minute data-dependant acquisition (DDA) method was setup on the Q Exactive Plus. The full MS1 scan from 400–1500 m/z was acquired in the Orbitrap at a resolution of 70,000 in profile mode with subsequent fragmentation of top 12 parent ions using the HCD cell and detection of fragment ions in the Orbitrap using centroid mode at a resolution of 17,500. The following MS method parameters were used: MS1 Automatic Gain Control (AGC) target was set to 3e6 with maximum injection time (IT) of 100ms, MS2 AGC was set to 1e5 with maximum IT of 50ms, isolation window was 1.6 Da, underfill ratio 2%, intensity threshold 4e4, normalized collision energy was set to 27, charge exclusion was set to fragment only 2+,3+ and 4+ charge state ions, apex trigger was deactivated, peptide match set to preferred and dynamic exclusion set to 45 seconds.

Data analysis

The mass spectrometry RAW files were uploaded into **MaxQuant** ver. 1.5.2.8 and searched with built-in **Andromeda search engine**^{20,21}. The search was performed with oxidation of methionine and N-terminal protein acetylation as variable modifications, carbamidomethylation of cysteine as a fixed modification, trypsin as the digestive enzyme with a maximum of 2 allowed missed cleavages. The first peptide search tolerance for both samples was 20ppm against a small 'human first-search' database

for the purpose of mass recalibration, whereas the main search was performed at 4.5 ppm against the [Human SwissProt protein database](#) (January 2015 release). The database was reversed to calculate the peptide and protein level false-discovery rate (set at 1%). Proteases were selected from the protein list by comparing the dataset to the Merops database. Candidate active proteases were subsequently selected based on relative protein abundance within the sample, catalytic type, molecular size of the mature protein and substrate specificity.

Validation of TMPRSS11D in CVF

Validation of TMPRSS11D was performed by preparing 10µg total protein unfractionated CVF sample and SEC fractionated CVF samples for gel electrophoresis as described previously. A total of 20µg HepG2 cell lysate (abcam, #ab7900) was included as a positive control as per manufacturer's instructions. Following gel electrophoresis and transfer of the proteins to a PDVF membrane, the membrane was blocked in 5% milk in TBS-T at 4°C overnight. The membrane was probed with anti-TMPRSS11D antibody (ab127031, abcam, RRID:AB_11129135) diluted 1 in 500 in 1% milk in TBS-T for 90 minutes at room temperature. Subsequently, the membrane was washed 3 times for 10 minutes with TBS-T and incubated with peroxidase conjugated goat anti rabbit secondary antibody (Jackson ImmunoResearch, #111-035-045) diluted 1 in 3000 in 1% milk in TBS-T for 45 minutes. The membrane was washed 4 times for 10 minutes with TBS-T prior to incubation with chemiluminescence substrate, exposure and development.

Production and purification of mature active KLK13

Recombinant active KLK13 was produced using a *Pichia pastoris* yeast expression system. Briefly, a PCR-amplified DNA fragment encoding the mature KLK13 isoform (36-277 aa) was cloned into the pPIC9 expression vector, in-frame with its α -secretion signal and the alcohol oxidase *AOX1* gene. Purified mature *KLK13* pPIC9 DNA construct was confirmed by sequencing using the 5'-*AOX1*, 3'-*AOX1* and the α -secretion signal vector-specific primers and the NCBI BLAST align program. The KLK13-pPIC9 construct was linearized with *SacI* enzyme and transformed into the KM71 *P. pastoris* strain via electroporation. A stable KM71 transformant was grown in 1 liter of buffered glycerol-complex medium (BMGY) media. After 2 days, yeast culture was centrifuged, and the cell pellet was resuspended in 300 ml of BMMY media (A600 = 10). Recombinant KLK13 expression was induced with 1% methanol for 5 days at 30°C in a shaking incubator (250 rpm). Recombinant KLK13 was purified from culture supernatant by ultraconcentration, serial dialysis, and centrifugation procedures, followed by cation-exchange chromatography using an automated ÄKTA FPLC system on a pre-equilibrated 5-ml cation-exchange HiTrap high performance Sepharose HP-SP column (GE Healthcare). Recombinant KLK13 was further purified using 10mL cation-exchange Source15S Tricorn™ column (GE Healthcare). The collected fractions were pooled, concentrated, analyzed by SDS-PAGE and Western blotting and stored at -80°C until further use. The concentration of purified protein was measured using a Coomassie protein assay and KLK13 ELISA as described previously²². The N-termini of the bands identified on SDS-PAGE gels were analyzed with N-terminal Edman sequencing.

Validation of KLK13 in CVF

Unfractionated CVF and SEC fractionated CVF samples were prepared for gel electrophoresis as described previously. A total of 1µg in-house produced recombinant KLK13 was included as a positive control. Following gel electrophoresis and protein transfer, the membrane was blocked in 5% milk in TBS-T at 4°C overnight. The membrane was probed with a in-house produced monoclonal anti-KLK13 antibody diluted 1 in 50 in 1% milk in TBS-T for 90 minutes at room temperature²³. Subsequently, the membrane was washed 3 times for 10 minutes with TBS-T and incubated with peroxidase conjugated goat anti mouse secondary antibody (Jackson ImmunoResearch, #115-035-146) 1 in 3000 diluted in 1% milk in TBS-T for 45 minutes. The membrane was washed 4 times for 10 minutes with TBS-T prior to incubation with chemiluminescence substrate (GE healthcare, #45000875), exposure and development.

An immunocapture method was developed to confirm the presence and activity of KLK13 in CVF. In this assay, 500ng of in-house produced monoclonal KLK13 antibody was coated overnight on a 96-well plate in coating buffer (50mM Tris, 0.05% Tween-20, pH 7.8). The plate was washed 3 times with washing buffer (50mM Tris, 150mM NaCl, 0.05% Tween-20, pH 7.8) and blocked with 1% bovine serum albumin (BSA) in activity buffer (100mM NaH₂PO₄/Na₂HPO₄, pH 8.5) for 90 minutes. The plate was washed 3 times with washing buffer prior to incubation with CVF samples (N=3) in a 1 in 5, 1 in 10 and 1 in 50 dilutions for 3 hours at room temperature. Activity buffer without active enzyme, IgG coated wells, and 6nM in-house produced recombinant KLK13 were included as a negative and positive controls respectively. The wells were washed extensively 6 times with washing buffer to remove any unbound protein. A final 0.5mM VPR-AMC substrate (Bachem, #4003460) was added to the wells and the resulting increase in fluorescence was measured in 1-minute intervals on a Wallac Envision fluorometer set at 355nm for excitation and 460nm for emission. Proteolytic KLK13 activity in CVF was semi-quantified by comparing the rate of substrate hydrolysis after subtraction of the fluorescence of enzyme-free reactions to the recombinant KLK13 activity.

The influence of pH on the proteolytic activity of KLK13 was tested by measuring the cleavage of fluorogenic substrate by 6nM recombinant KLK13 in buffer with pH ranging from 3.5 to 10.0 in 0.5 increments. Fluorescence was measured every minute for 15 minutes on a Wallac Envision fluorometer (Perkin-Elmer) set at 355nm for excitation and 460nm for emission. Proteolytic activity was quantified by calculating the rate of substrate hydrolysis after subtraction of the fluorescence of enzyme-free reactions relative to proteolytic activity at pH 8.0. All reactions were performed at 37°C in triplicate on 2 separate days.

Results

Investigation of proteolytic activity in CVF

A total of 85 proteases were identified in the CVF proteome based on samples from healthy, non-pregnant women of reproductive age⁷. As shown in [Figure 1](#), proteases of different catalytic classes are present in the entire relative abundance spectrum

Figure 1. The ranked relative abundance of proteases in the cervical-vaginal fluid (CVF) proteome. Visualization of the ranked relative abundance of all proteins in CVF (1,065 proteins, grey dots) highlighting serine proteases (36 proteins, red dots), cysteine proteases (13 proteins, blue dots), threonine proteases (13 proteins, green dots) metalloproteinases (10 proteins, yellow dots). Aspartic acid proteases (1 protein), mixed catalytic type proteases (3 proteins) and unassigned proteases (4 proteins) were also identified in CVF.

of the CVF proteome. Multiple serine proteases rank among the most abundant proteins in CVF. As can be seen in [Figure 2A](#), the trypsin-like proteolytic activity in CVF is optimal at slightly alkaline pH levels (pH 7.5-9). Almost half of the maximal trypsin-like proteolytic activity in CVF remains at pH 6.0, whereas there is negligible trypsin-like proteolytic activity at pH 4.5 or below. The presence of PMSF and STI significantly reduced the trypsin-like proteolytic activity in CVF ($p < 0.05$), whereas EDTA did not impact the proteolytic activity in CVF significantly ([Figure 2B](#)).

Visualization of active, trypsin-like proteases in CVF

Active proteases present in CVF from healthy, non-pregnant women of reproductive age were visualized using the ABP probe, which binds trypsin-like active proteases in a covalent and specific manner¹⁹. As illustrated in [Figure 3A](#), trypsin-like protease activity in CVF is present at 2 separate molecular weight (MW) bands at approximately 28 and 35kDa. Apart from differences in the intensity of the bands, the observed expression pattern was nearly identical among the different CVF samples. Next, we investigated whether the trypsin-like protease activity in CVF can be attributed to proteases of certain catalytic types. Complete cessation of trypsin-like activity in CVF was accomplished by incubation of the CVF samples with the

irreversible protease inhibitor PMSF, targeting both serine and cysteine proteases, prior to coupling to the ABP ([Figure 3B](#)). Additionally, incubation of CVF with reversible serine protease inhibitor STI resulted in a near complete inhibition of the protease activity in CVF compared to the uninhibited control condition ([Figure 3C](#)). Inhibition of metalloproteinases via incubation with EDTA did not affect the trypsin-like proteolytic activity in CVF ([Figure 3B](#)). As expected, no active proteases were detected in the control condition without probe addition ([Figure 3D](#)).

Identification of active proteases TMPRSS11D and KLK13

SEC fractionation of CVF resulted in the successful separation of the high and low MW proteases as demonstrated by the split in proteolytic activity measured in fractionated CVF using the fluorogenic VPR-AMC substrate ([Figure 4A](#)) and subsequent visualization of active proteases in CVF using the ABP ([Figure 4B](#)). Both the high and low MW bands were excised and resolved separately with mass spectrometry resulting in the identification of approximately 100 proteins for the high MW and low MW bands ([Figure 4C-D](#)). Candidate active proteases were selected based on relative protein abundance among the sample proteome, serine proteolytic catalytic type, correct molecular size and trypsin-like substrate specificity. This approach resulted in the identification of KLK13 as a

Figure 2. Trypsin-like proteolytic activity in cervical-vaginal fluid (CVF). (A) Trypsin-like proteolytic activity in CVF is highly pH dependent as demonstrated by the cleavage of fluorogenic trypsin-like VPR-AMC substrate by proteases in CVF. Grey areas represent the CVF pH during infections and post-menopausal status (pH 5–6.5) and after sperm ejaculation (pH 7.2) Trypsin-like activity is shown as relative to maximum activity at pH 9.0 (B) Trypsin-like proteolytic activity is significantly inhibited by PMSF and STI, whereas EDTA has no significant effect. The trypsin-like activity is shown as relative to the activity observed in uninhibited CVF.

candidate protease for the high MW band and TMPRSS11D as the candidate active protease in the low MW band.

Validation of TMPRSS11D and KLK13 in CVF

A Western blot showed TMPRSS11D at the correct MW in unfractionated CVF samples (Figure 5). Furthermore, TMPRSS11D is detected in the CVF fractions corresponding to the low MW band as expected.

Mature, active recombinant KLK13 was produced in a *P. pastoris* expression system. The KLK13 750bp PCR construct was successfully ligated into a eukaryotic pPIC9 vector as confirmed by DNA sequencing. The pPIC9-*klk13* vector was subsequently linearized by *SacI* enzyme digestion and electroporated into *P. pastoris* KM71 cells. Gel electrophoresis of the KLK13 protein, isolated from the methanol induced yeast cell culture medium in a multi-step purification and concentration process, resulted in the visualization of KLK13 (Figure 6A). PNGaseF treatment revealed that the higher MW band is the result of glycosylation at 225N. (Figure 6B). KLK13 identity was confirmed by mass spectrometry analysis.

KLK13 is present in unfractionated CVF at multiple sizes that correspond with a smaller, potentially degraded form of KLK13, KLK13 bound to endogenous inhibitors and KLK13 in its active mature form (Figure 7A). Analysis of the fractionated CVF sample demonstrated that the presence of KLK13 at the correct MW in the fractions corresponding with the high MW band of Figure 3 and Figure 4. The cleavage of the fluorescent substrate by immunocaptured KLK13 showed that at least a proportion of KLK13 is present in CVF in its mature, active form, which is not bound to endogenous inhibitors (Figure 7B). The proteolytic activity of recombinant KLK13 was demonstrated to be highly pH-dependent with maximum activity observed at pH 8.0 and minimal activity at the physiological pH observed in CVF (<6) (Figure 7C).

Discussion

In-depth proteomic analysis of CVF of healthy, non-pregnant women previously revealed the presence of numerous proteases, including a large number of serine proteases, in this fluid. Indeed, multiple serine proteases are among the most abundant proteins in the CVF proteome and incubation of CVF with serine protease

Figure 3. Visualization of active trypsin-like proteases in cervical-vaginal fluid (CVF). (A) Active trypsin-like proteases in CVF (N=10) were coupled to the biotinylated ABP probe and visualized following gel electrophoresis. Trypsin-like proteolytic activity was present in two separate bands (28kDa and 35kDa) in each of the samples. (B) Co-incubation of CVF with PMSF prior to coupling to the ABP probe resulted in the inhibition of active trypsin-like proteolytic activity, whereas co-incubation with EDTA did not effect active trypsin-like proteolytic activity (C) Incubation with STI prior to labeling CVF with the ABP probe inhibited the trypsin-like proteolytic activity in CVF compared to the control condition (D) Negative control condition incubated without ABP probe showed no trypsin-like proteolytic activity in experimental samples.

inhibitors significantly decreased proteolytic activity in CVF. Both findings highlight the functional importance of the serine protease family in CVF.

In the current study, we performed a functional proteomic approach coupling a biotinylated ABP probe with trypsin-like specificity with mass spectrometry, to profile the active proteases in CVF. This powerful approach resulted in the identification of serine proteases KLK13 and TMPRSS11D as putative active proteolytic enzymes in CVF.

TMPPRSS11D, better known as human airway trypsin-like protease or HAT, displays trypsin-like activity and belongs to the type II transmembrane serine proteases²⁴. TMPPRSS11D is synthesized as an inactive zymogen which requires proteolytic cleavage to release the soluble extracellular 27kDa mature active form^{25,26}. This transmembrane protein is expressed in the squamous epithelial cells of the vagina and the glandular cells of the endometrium and was detected in the CVF proteome^{7,27}. Mostly studied in the context of respiratory diseases, TMPPRSS11D is a versatile protein whose functions include fibrinolysis, PAR-2

Figure 4. Trypsin-like proteolytic activity in size exclusion (SEC) fractionated cervical-vaginal fluid (CVF). (A) trypsin-like activity was quantified in fractions F36 – F46 in SEC fractionated CVF using VPR-AMC substrate (B) Visualization of separation of high (F36-F38) and low (F42-F46) MW band containing trypsin-like proteolytic activity in SEC fractionated CVF (C) Ranked relative abundance based on average MS1 area of proteases (red dots, KLK13 as star) in high MW fractions across CVF proteome (D) Ranked relative abundance based on average MS1 area of proteases (red dots, TMPRSS11D as star) in low MW fractions across CVF proteome. For more comments see text.

receptor activation and the processing of viral glycoproteins²⁸. Interestingly, activation of the PAR-2 receptor negatively affects the structural integrity of the vaginal epithelium prompting the hypothesis that TMPRSS11D is involved in barrier function modulation in the lower female reproductive system^{29–32}. Additionally, TMPRSS11D is differentially expressed in the peri-implantation uterine luminal epithelium in mice where it is putatively involved in morphological changes required for the initial attachment of the embryo to the luminal epithelium³³. It is unknown whether TMPRSS11D plays a similar role in the human endometrial environment.

KLK13 belongs to the kallikrein-related peptidase family; a group of 15 secreted serine proteases with either tryptic or chymotryptic substrate specificity. KLKs are expressed throughout the human body with the highest expression levels observed in the fluids and tissues of the male and female reproductive systems^{34,35}. Studies on KLK13 have predominantly focused on its applicability as a cancer biomarker, leaving the physiological role of this protein not well understood^{34,36–40}. *In vitro* assays showed that despite being present in active form and unbound to endogenous inhibitors, KLK13 activity will largely be inhibited due to the low pH in CVF.

Figure 5. Validation of TMPRSS11D in cervical-vaginal fluid (CVF). TMPRSS11D is detected in unfractionated CVF and in F42-F46 of SEC fractionated CVF corresponding with the proteolytic activity visualized with the ABP in the low MW band. HepG2 cell lysate is included as a positive control.

Figure 6. Production of recombinant active KLK13 protein. (A) Silver staining of reduced SDS-PAGE of KLK13 following purification with band visible at 30kDa. The band was found to contain KLK13 sequences by mass spectrometry and recognized by anti-KLK13 antibody by western blot (WB) (B) Coomassie staining of reduced SDS-PAGE of purified KLK13 showing PNGase F treatment increasing the 28kDa band intensity.

KLK13 is the highest abundant KLK member among a cassette of KLKs that are co-expressed in CVF³⁴. The concentration of KLK13 in CVF is approximately 12 mg/L (data not shown); only KLK2 and KLK3 are found at higher concentrations in the male reproductive system⁴¹. Both KLK5 and KLK12 have been studied in the lower female reproductive tract and are thought to be involved in the desquamation of the vaginal epithelium, facilitation of sperm transport towards the oocyte and the processing of antimicrobial peptides in CVF^{42,43}. KLK13 could also be involved in these processes either directly or, based on the detection of multiple members of the KLK family in CVF, via participation in a proteolytic cascade in which proteases

activate consecutive proteases thereby amplifying the proteolytic potential⁴⁴.

In conclusion, the current study provides insights on the proteolytic functioning in the lower female reproductive tract. Fitting in the framework that serine proteases are the predominant source of trypsin-like proteolytic activity in CVF, ABP proteomics resulted in the identification of KLK13 and TMPRSS11D as candidate active proteases in this complex biological fluid. Both proteolytic enzymes exert their effects extracellularly in CVF which led us to believe that the activity of these enzymes will be largely inhibited by the low pH⁴⁵. Based on the highly pH-dependent

Figure 7. Validation of KLK13 presence in cervical-vaginal fluid (CVF). (A) Western blot with KLK13 monoclonal antibody detected bands with multiple molecular sizes in unfractionated CVF. KLK13 was detected as a single band around 30-35kDa in SEC fractionated CVF F36-38 corresponding with the proteolytic activity visualized with the ABP probe in the high MW band. In-house produced recombinant KLK13 was included as a positive control (B) Immunocapture assay demonstrating the dilution dependent presence of KLK13 in CVF in active form and not bound to endogenous inhibitors (C) Effect of pH on KLK13 trypsin-like proteolytic activity showing pH dependency with optimum activity observed at pH 8.0.

trypsin-like proteolytic activity in this complex biological fluid, the possibility that pH acts as a regulatory mechanism to control proteolytic activity in CVF was raised. As can be seen by the grey overlay in [Figure 2A](#), proteolytic activity is absent at physiological pH levels (4.5 or below). It is possible however that conditions characterized by an elevated pH would allow for moderate to high levels of protease activity, and more

specifically KLK13 activity, in CVF. It is known that the vaginal pH shows a dramatic rise to 7.2 within seconds after sperm ejaculation⁴⁶. It is therefore not unlikely that KLK13 could be activated just after ejaculation during sexual intercourse, participates in a proteolytic cascade with proteases present in the ejaculate and initiates events associated with fertility. Additionally, CVF pH is elevated during certain vaginal infections

and in postmenopausal women^{47,48}. These conditions provide a window of opportunity for proteolytic activity in the lower female reproductive system. The current study provides a framework for future investigations aimed at understanding proteolytic functioning within the complexities of the lower female reproductive system.

Data availability

Underlying data is available from figshare:

Dataset 1. Ranked relative abundance proteases in CVF. <https://dx.doi.org/10.6084/m9.figshare.7137920.v1>⁴⁹

Dataset 2. Trypsin-like proteolytic activity in CVF. <https://dx.doi.org/10.6084/m9.figshare.7137938.v1>⁵⁰

Dataset 3. Visualization of active trypsin-like proteases in CVF. <https://dx.doi.org/10.6084/m9.figshare.7137941.v1>⁵¹

Dataset 4. Trypsin-like proteolytic activity in size exclusion (SEC) fractionated CVF. <https://dx.doi.org/10.6084/m9.figshare.7137944.v1>⁵²

Dataset 5. Validation of TMPRSS1D in CVF. <https://dx.doi.org/10.6084/m9.figshare.7137947.v1>⁵³

Dataset 6. Production of recombinant active of protein KLK13 protein. <https://dx.doi.org/10.6084/m9.figshare.7137953.v1>⁵⁴

Dataset 7. Validation of KLK13 presence in CVF. <https://dx.doi.org/10.6084/m9.figshare.7137962.v1>⁵⁵

All data is available under a CC by 4.0 Universal licence

Grant information

The author(s) declared that no grants were involved in supporting this work.

Acknowledgements

The authors would like to thank Professor Brendan Gilmore (Queen's University Belfast) for providing the activity-based probe and Dr. Katerina Oikonomopoulou (University Health Network, Toronto) for her advice and suggestions during the preparation of this manuscript.

References

1. Rawlings ND, Barrett AJ, Finn R: **Twenty years of the MEROPS database of proteolytic enzymes, their substrates and inhibitors.** *Nucleic Acids Res.* 2016; **44**(D1): D343–50.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
2. Kim SO, Oh KJ, Lee HS, *et al.*: **Expression of aquaporin water channels in the vagina in premenopausal women.** *J Sex Med.* 2011; **8**(7): 1925–30.
[PubMed Abstract](#) | [Publisher Full Text](#)
3. Traish AM, Botchevar E, Kim NN: **Biochemical factors modulating female genital sexual arousal physiology.** *J Sex Med.* 2010; **7**(9): 2925–46.
[PubMed Abstract](#) | [Publisher Full Text](#)
4. Amaral E, Perdigão A, Souza MH, *et al.*: **Postcoital testing after the use of a bio-adhesive acid buffering gel (ACIDFORM) and a 2% nonoxonyl-9 product.** *Contraception.* 2004; **70**(6): 492–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
5. Suarez SS, Pacey AA: **Sperm transport in the female reproductive tract.** *Hum Reprod Update.* 2006; **12**(1): 23–37.
[PubMed Abstract](#) | [Publisher Full Text](#)
6. Yarbrough VL, Winkle S, Herbst-Kralovetz MM: **Antimicrobial peptides in the female reproductive tract: a critical component of the mucosal immune barrier with physiological and clinical implications.** *Hum Reprod Update.* 2015; **21**(3): 353–77.
[PubMed Abstract](#) | [Publisher Full Text](#)
7. Muytjens CMJ, Yu Y, Diamandis EP: **Discovery of Antimicrobial Peptides in Cervical-Vaginal Fluid from Healthy Nonpregnant Women via an Integrated Proteome and Peptidome Analysis.** *Proteomics.* 2017; **17**(21): 1600461–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
8. Witkin SS, Ledger WJ: **Complexities of the uniquely human vagina.** *Sci Transl Med.* 2012; **4**(132): 132fs11.
[PubMed Abstract](#) | [Publisher Full Text](#)
9. Ravel J, Gajer P, Abdo Z, *et al.*: **Vaginal microbiome of reproductive-age women.** *Proc Natl Acad Sci U S A.* 2011; **108** Suppl 1: 4680–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
10. Boskey ER, Telsch KM, Whaley KJ, *et al.*: **Acid production by vaginal flora in vitro is consistent with the rate and extent of vaginal acidification.** *Infect Immun.* 1999; **67**(10): 5170–5.
[PubMed Abstract](#) | [Free Full Text](#)
11. Gorodeski GI: **Effects of estrogen on proton secretion via the apical membrane in vaginal-ectocervical epithelial cells of postmenopausal women.** *Menopause.* 2005; **12**(6): 679–84.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
12. Gorodeski GI, Hopfer U, Liu CC, *et al.*: **Estrogen acidifies vaginal pH by up-regulation of proton secretion via the apical membrane of vaginal-ectocervical epithelial cells.** *Endocrinology.* 2005; **146**(2): 816–24.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
13. Yang P, Liu K: **Activity-based protein profiling: recent advances in probe development and applications.** *Chembiochem.* 2015; **16**(5): 712–24.
[PubMed Abstract](#) | [Publisher Full Text](#)
14. Barglow KT, Cravatt BF: **Activity-based protein profiling for the functional annotation of enzymes.** *Nat Methods.* 2007; **4**(10): 822–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
15. Serim S, Haedke U, Verhelst SH: **Activity-based probes for the study of proteases: recent advances and developments.** *ChemMedChem.* 2012; **7**(7): 1146–59.
[PubMed Abstract](#) | [Publisher Full Text](#)
16. Mayers MD, Moon C, Stupp GS, *et al.*: **Quantitative Metaproteomics and Activity-Based Probe Enrichment Reveals Significant Alterations in Protein Expression from a Mouse Model of Inflammatory Bowel Disease.** *J Proteome Res.* 2017; **16**(2): 1014–26.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
17. North BB, Oldham MJ: **Preclinical, clinical, and over-the-counter postmarketing experience with a new vaginal cup: menstrual collection.** *J Womens Health (Larchmt).* 2011; **20**(2): 303–11.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
18. Valore EV, Park CH, Igreti SL, *et al.*: **Antimicrobial components of vaginal fluid.** *Am J Obstet Gynecol.* 2002; **187**(3): 561–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
19. Pan Z, Jeffery DA, Chehade K, *et al.*: **Development of activity-based probes for trypsin-family serine proteases.** *Bioorg Med Chem Lett.* 2006; **16**(11): 2882–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
20. Cox J, Mann M: **MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification.** *Nat Biotechnol.* 2008; **26**(12): 1367–72.
[PubMed Abstract](#) | [Publisher Full Text](#)
21. Cox J, Neuhauser N, Michalski A, *et al.*: **Andromeda: a peptide search engine integrated into the MaxQuant environment.** *J Proteome Res.* 2011; **10**(4): 1794–805.
[PubMed Abstract](#) | [Publisher Full Text](#)
22. Kapadia C, Chang A, Sotiropoulou G, *et al.*: **Human kallikrein 13: production and purification of recombinant protein and monoclonal and polyclonal antibodies, and development of a sensitive and specific immunofluorometric assay.** *Clin Chem.* 2003; **49**(1): 77–86.
[PubMed Abstract](#) | [Publisher Full Text](#)
23. Kapadia C, Chang A, Sotiropoulou G, *et al.*: **Human kallikrein 13: production and purification of recombinant protein and monoclonal and polyclonal antibodies, and development of a sensitive and specific immunofluorometric assay.** *Clin*

- Chem. 2003; 49(1): 77–86.
[PubMed Abstract](#) | [Publisher Full Text](#)
24. Wysocka M, Spichalska B, Lesner A, *et al.*: **Substrate specificity and inhibitory study of human airway trypsin-like protease.** *Bioorg Med Chem.* 2010; 18(15): 5504–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
 25. Kato M, Hashimoto T, Shimomura T, *et al.*: **Hepatocyte growth factor activator inhibitor type 1 inhibits protease activity and proteolytic activation of human airway trypsin-like protease.** *J Biochem.* 2012; 151(2): 179–87.
[PubMed Abstract](#) | [Publisher Full Text](#)
 26. Yasuoka S, Ohnishi T, Kawano S, *et al.*: **Purification, characterization, and localization of a novel trypsin-like protease found in the human airway.** *Am J Respir Cell Mol Biol.* 1997; 16(3): 300–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
 27. Uhlén M, Fagerberg L, Hallström BM, *et al.*: **Proteomics. Tissue-based map of the human proteome.** *Science.* 2015; 347(6220): 1260419.
[PubMed Abstract](#) | [Publisher Full Text](#)
 28. Menou A, Duitman J, Flajolet P, *et al.*: **Human airway trypsin-like protease, a serine protease involved in respiratory diseases.** *Am J Physiol Lung Cell Mol Physiol.* 2017; 312(5): L657–L68.
[PubMed Abstract](#) | [Publisher Full Text](#)
 29. Chokki M, Eguchi H, Hamamura I, *et al.*: **Human airway trypsin-like protease induces amphiregulin release through a mechanism involving protease-activated receptor-2-mediated ERK activation and TNF alpha-converting enzyme activity in airway epithelial cells.** *FEBS J.* 2005; 272(24): 6387–99.
[PubMed Abstract](#) | [Publisher Full Text](#)
 30. Li Y, Feng C, Wei X, *et al.*: **Activation of protease-activated receptor-2 disrupts vaginal epithelial barrier function.** *Cell Biol Int.* 2014; 38(11): 1247–51.
[PubMed Abstract](#) | [Publisher Full Text](#)
 31. Matsushima R, Takahashi A, Nakaya Y, *et al.*: **Human airway trypsin-like protease stimulates human bronchial fibroblast proliferation in a protease-activated receptor-2-dependent pathway.** *Am J Physiol Lung Cell Mol Physiol.* 2006; 290(2): L385–95.
[PubMed Abstract](#) | [Publisher Full Text](#)
 32. Miki M, Nakamura Y, Takahashi A, *et al.*: **Effect of human airway trypsin-like protease on intracellular free Ca²⁺ concentration in human bronchial epithelial cells.** *J Med Invest.* 2003; 50(1–2): 95–107.
[PubMed Abstract](#)
 33. Xiao S, Diao H, Zhao F, *et al.*: **Differential gene expression profiling of mouse uterine luminal epithelium during periimplantation.** *Reprod Sci.* 2014; 21(3): 351–62.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 34. Shaw JL, Diamandis EP: **Distribution of 15 human kallikreins in tissues and biological fluids.** *Clin Chem.* 2007; 53(8): 1423–32.
[PubMed Abstract](#) | [Publisher Full Text](#)
 35. Muytjens CM, Vasilou SK, Oikonomopoulou K, *et al.*: **Putative functions of tissue kallikrein-related peptidases in vaginal fluid.** *Nat Rev Urol.* 2016; 13(10): 596–607.
[PubMed Abstract](#) | [Publisher Full Text](#)
 36. Nohara K, Yamada K, Yamada L, *et al.*: **Expression of kallikrein-related peptidase 13 is associated with poor prognosis in esophageal squamous cell carcinoma.** *Gen Thorac Cardiovasc Surg.* 2018; 66(6): 351–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
 37. Dettmar L, Ahmed N, Kotzsch M, *et al.*: **Advanced high-grade serous ovarian cancer: inverse association of KLK13 and KLK14 mRNA levels in tumor tissue and patients' prognosis.** *J Cancer Res Clin Oncol.* 2018; 144(6): 1109–18.
[PubMed Abstract](#) | [Publisher Full Text](#)
 38. Lin Q, Mao W, Wu Q, *et al.*: **Downregulation of KLK13 promotes the invasiveness and metastasis of oesophageal squamous cell carcinoma.** *Biomed Pharmacother.* 2017; 96: 1008–15.
[PubMed Abstract](#) | [Publisher Full Text](#)
 39. Tokas T, Avgeris M, Alamanis C, *et al.*: **Downregulated KLK13 expression in bladder cancer highlights tumor aggressiveness and unfavorable patients' prognosis.** *J Cancer Res Clin Oncol.* 2017; 143(3): 521–32.
[PubMed Abstract](#) | [Publisher Full Text](#)
 40. Gueugnon F, Barascu A, Mavridis K, *et al.*: **Kallikrein-related peptidase 13: an independent indicator of favorable prognosis for patients with nonsmall cell lung cancer.** *Tumour Biol.* 2015; 36(7): 4979–86.
[PubMed Abstract](#) | [Publisher Full Text](#)
 41. Shaw JL, Diamandis EP: **Distribution of 15 human kallikreins in tissues and biological fluids.** *Clin Chem.* 2007; 53(8): 1423–32.
[PubMed Abstract](#) | [Publisher Full Text](#)
 42. Shaw JL, Diamandis EP: **A potential role for tissue kallikrein-related peptidases in human cervico-vaginal physiology.** *Biol Chem.* 2008; 389(6): 681–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
 43. Shaw JL, Petraki C, Watson C, *et al.*: **Role of tissue kallikrein-related peptidases in cervical mucus remodeling and host defense.** *Biol Chem.* 2008; 389(12): 1513–22.
[PubMed Abstract](#) | [Publisher Full Text](#)
 44. Yoon H, Laxmikanthan G, Lee J, *et al.*: **Activation profiles and regulatory cascades of the human kallikrein-related peptidases.** *J Biol Chem.* 2007; 282(44): 31852–64.
[PubMed Abstract](#) | [Publisher Full Text](#)
 45. Ma B, Forney LJ, Ravel J: **Vaginal microbiome: rethinking health and disease.** *Annu Rev Microbiol.* 2012; 66: 371–89.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 46. Fox CA, Meldrum SJ, Watson BW: **Continuous measurement by radio-telemetry of vaginal pH during human coitus.** *J Reprod Fertil.* 1973; 33(1): 69–75.
[PubMed Abstract](#) | [Publisher Full Text](#)
 47. Caillouette JC, Sharp CF Jr, Zimmerman GJ, *et al.*: **Vaginal pH as a marker for bacterial pathogens and menopausal status.** *Am J Obstet Gynecol.* 1997; 176(6): 1270–5; discussion 1275–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
 48. Milsom I, Arvidsson L, Ekelund P, *et al.*: **Factors influencing vaginal cytology, pH and bacterial flora in elderly women.** *Acta Obstet Gynecol Scand.* 1993; 72(4): 286–91.
[PubMed Abstract](#) | [Publisher Full Text](#)
 49. Muytjens C: **Ranked relative abundance proteases in CVF.** 2018.
<http://www.doi.org/10.6084/m9.figshare.7137920.v1>
 50. Muytjens C: **Trypsin-like proteolytic activity in CVF.** 2018.
<http://www.doi.org/10.6084/m9.figshare.7137938.v1>
 51. Muytjens C: **Visualization of active trypsin-like proteases in CVF.** 2018.
<http://www.doi.org/10.6084/m9.figshare.7137941.v1>
 52. Muytjens C: **Trypsin-like proteolytic activity in size exclusion (SEC) fractionated CVF.** 2018.
<http://www.doi.org/10.6084/m9.figshare.7137944.v1>
 53. Muytjens C: **Validation of TMPRSS1D in CVF.** 2018.
<http://www.doi.org/10.6084/m9.figshare.7137947.v1>
 54. Muytjens C: **Production of recombinant active of protein KLK13.** 2018.
<http://www.doi.org/10.6084/m9.figshare.7137953.v1>
 55. Muytjens C: **Validation of KLK13 presence in CVF.** 2018.
<http://www.doi.org/10.6084/m9.figshare.7137962.v1>

Open Peer Review

Current Peer Review Status:

Version 2

Reviewer Report 09 January 2019

<https://doi.org/10.5256/f1000research.19125.r42238>

© 2019 Deraison C. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Céline Deraison

Digestive Health Research Institute (IRSD), U1220, INSERM, Toulouse, France

Thanks for clarification and changes.

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Version 1

Reviewer Report 22 November 2018

<https://doi.org/10.5256/f1000research.17754.r40431>

© 2018 Deraison C. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Céline Deraison

Digestive Health Research Institute (IRSD), U1220, INSERM, Toulouse, France

The presented study aimed to characterize active serine proteases in cervicovaginal fluid (CVF). Active serine proteases were profiled using activity based probe from human CVF highlighting 2 close bands. A whole proteomic strategy was performed using human CVF and 2 proteases were deeper characterised, KLK3 and TMPRSS11D.

CVF is a particular fluid since the pH is very low and also numerous proteases. The study is well designed and based on human samples, increasing the interest of the study. The manuscript is

well written. However different points will need to be discussed or explained.

1. How could we explain why using ABP only two bands are highlighted (figure3) since 36 serine proteases were identified on MS/MS study (Figure1)?
2. A clear correlation between activity of KLK13 and TMPRSS11D and their presence in CVF is not well established. Why authors did not perform MS/MS approach on active proteases enriched sample after ABP trapping?
3. Authors claimed that KLK3 active form was present in CVF sample. However in figure 3 and 4 it not clear that immunoband from recombinant active KLK13 and higher band from ABP treated CVF are at the same size. In addition, why active recombinant KLK3 showed two bands after ABP trapping? Why inactive mutant KLK13 is also trapped by ABP? What is the identity of mutation? Why KLK13 is always present on gels in figure 3? Authors suggested that KLK13 is active in CVF sample since proteolytic activity is detected with immunocaptured fraction using antibody against KLK13. "The cleavage of the fluorescent substrate by immunocaptured KLK13 showed that at least a proportion of KLK13 is present in CVF in its mature, active form, which is not bound to endogenous inhibitors. In addition, the used antibody was produced in the lab. Could authors provide a bibliographic reference illustrating the specificity of the antibody since the group of KLK contains some very similar proteins.
4. In figure 4, it could be informative to highlight KLK13 and TMPRSS11D on graphs. On this figure, it is not clear how is ranked the intensity of each protein. Does it correspond to the quantity of peptides identified by MS/MS for each protein?
5. In discussion section, 2 sentences implied that a direct identification of active protease targeted by ABP was performed. Please, correct these sentences ("This powerful approach resulted in the identification of serine proteases KLK13 and TMPRSS11D as major active proteolytic enzymes in CVF. ABP proteomics resulted in the identification of KLK13 and TMPRSS11D as active proteases in this complex biological fluid.)

Minor comments:

- Figure 2: The graph represents the "relative trypsin-like activity". What is the reference?
- What does NRT mean?
- The biological concentration of KLK13 is compared to KLK2 and KLK3 in sperm ("The concentration of KLK13 in CVF is approximately 12 mg/L (data not shown); only KLK2 and KLK3 are found at higher concentrations in the male reproductive system). It would be interesting to support this sentence with a bibliographic reference.

Is the work clearly and accurately presented and does it cite the current literature?

Yes

Is the study design appropriate and is the work technically sound?

Yes

Are sufficient details of methods and analysis provided to allow replication by others?

Partly

If applicable, is the statistical analysis and its interpretation appropriate?

Yes

Are all the source data underlying the results available to ensure full reproducibility?

Yes

Are the conclusions drawn adequately supported by the results?

Yes

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response (F1000Research Advisory Board Member) 08 Dec 2018

Eleftherios P Diamandis, Mount Sinai Hospital, Toronto, Canada

1. How could we explain why using ABP only two bands are highlighted (figure3) since 36 serine proteases were identified on MS/MS study (Figure1)?

The ABP recognizes only active serine proteases, whereas the MS/MS study aims to identify all proteases in CVF regardless of their functional status. The difference in the number of identified proteases (36 in MS/MS versus 2 clusters using the ABP) is most likely due to state of the proteases. A number of proteases will be present in CVF, but in zymogen form or closely bound to endogenous inhibitors. These proteases will be identified using MS, but would not be visible on the ABP blot since these proteins do not exert proteolytic activity.

1. A clear correlation between activity of KLK13 and TMPRSS11D and their presence in CVF is not well established. Why authors did not perform MS/MS approach on active proteases enriched sample after ABP trapping?

The availability of the ABP was a limiting factor in this study thereby preventing us to perform MS/MS on an ABP-enriched samples. We aimed to establish the correlation by showing that TMPRSS11D is present in CVF at the correct MW and fractionated CVF in the expected fractions. For KLK13, we also showed that KLK13 is present in CVF and fractionated CVF at the correct MW and in the expected fractions. Additionally, we using the immunocapture assay we demonstrated that (a proportion of) KLK13 is present in CVF in active form without its prodomain or bound to endogenous inhibitors.

1. Authors claimed that KLK3 active form was present in CVF sample. However in figure 3 and 4 it not clear that immunoband from recombinant active KLK13 and higher band from ABP treated CVF are at the same size. In addition, why active recombinant KLK3 showed two bands after ABP trapping? Why inactive mutant KLK13 is also trapped by ABP? What is the identity of mutation? Why KLK13 is always present on gels in figure 3? Authors suggested that KLK13 is active in CVF sample since proteolytic activity is detected with immunocaptured fraction using antibody against KLK13. "The cleavage of the fluorescent substrate by immunocaptured KLK13 showed that at least a proportion of KLK13 is present in CVF in its mature, active form, which is not bound to endogenous inhibitors. In addition, the used antibody was produced in the lab. Could authors provide a bibliographic reference illustrating the specificity of the antibody since the

group of KLK contains some very similar proteins.

The data in figure 3 and 4 demonstrating KLK13 in CVF is supported by additional evidence from the mass spectrometry analysis indicating that KLK13 is abundantly present in the bands corresponding to the higher MW band from the ABP-treated CVF. The active recombinant KLK13 shows 2 bands after ABP trapping most likely due to glycosylation. This affects the MW of the protein, while at the same time still allowing the activity of the protease. KLK13 is visible as 2 bands: one glycosylated and one not glycosylated. A logical explanation for the presence of KLK13 throughout the gel in figure 4 is due to the high abundance of this protein in CVF. It is frequently observed that high abundance proteins will not separate clearly in the expected fractions, but rather are present throughout the fractions. We expect that this is the case for KLK13 in fractionated CVF. KLK13 was inactivated not by introducing a mutation, but via incubation with the potent irreversible serine protease inhibitor PMSF. There are two explanations that clarify the small band present in the inactivated KLK13. It is possible that the band in inactive KLK13 is due to the proximity to the active recombinant KLK13 and is a result of spillover from the KLK13 lane into the inactive KLK13 lane. Alternatively, it is possible that KLK13 was not completely inactivated by PMSF resulting in the greatly diminished band shown on the blot. We have provided the reference in the manuscript for the production of the monoclonal KLK13 antibody used in this study.

- 1. In figure 4, it could be informative to highlight KLK13 and TMPRSS11D on graphs. On this figure, it is not clear how is ranked the intensity of each protein. Does it correspond to the quantity of peptides identified by MS/MS for each protein?**

We agree that figure 4 will be improved by highlighting KLK13 and TMPRSS11D. We have adjusted the figure in the manuscript accordingly. The proteins were ranked according to the intensity of each protein for which we used the average MS1 area of each protein as a proxy measure of protein abundance. We have adjusted the legend of the figure to reflect this change.

- 1. In discussion section, 2 sentences implied that a direct identification of active protease targeted by ABP was performed. Please, correct these sentences ('This powerful approach resulted in the identification of serine proteases KLK13 and TMPRSS11D as major active proteolytic enzymes in CVF. ABP proteomics resulted in the identification of KLK13 and TMPRSS11D as active proteases in this complex biological fluid.')**

We agree with the reviewer and have changed these sentences in the manuscript accordingly.

Minor comments:

- o Figure 2: The graph represents the "relative trypsin-like activity". What is the reference?**

For figure 2A the trypsin-like activity is relative to the trypsin-like activity measured at pH 9.0. This is the pH at which maximum trypsin-like activity was observed. In figure 2B, the trypsin-like activity is presented as relative to the activity in CVF without any inhibitors. We have adjusted the wording in the legend to better reflect this.

- **What does NRT mean?**

The 225NRT stands for the N-R-T amino acids in the KLK13 sequence. We have changed the wording in the manuscript to reflect that the glycosylation site is 225N.

- **The biological concentration of KLK13 is compared to KLK2 and KLK3 in sperm ("The concentration of KLK13 in CVF is approximately 12 mg/L (data not shown); only KLK2 and KLK3 are found at higher concentrations in the male reproductive system). It would be interesting to support this sentence with a bibliographic reference.**

We have included the appropriate reference to support the biological concentrations of KLKs in the CVF and seminal plasma.

Competing Interests: No competing interests were disclosed.

Reviewer Report 01 November 2018

<https://doi.org/10.5256/f1000research.17754.r39959>

© 2018 Pampalakis G. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Georgios Pampalakis

Department of Pharmacy, School of Health Sciences, University of Patras, Patras, Greece

The study uses functional proteomics and specifically Activity-Based Probe proteomics to identify the active proteases in cervicovaginal fluid (CVF). CVF is an interesting biological fluids because it contains high level of protease (and up to now their activation status was not known) and very low pH (<4.5).

The study is well designed. There are a few minor comments that will help the readers to understand better the findings.

Specifically:

1. What is the structure of the ABP used in the present study? (the ref 19 describes the synthesis of more than 1 ABP for probing trypsin-like activities).
2. For their proteomic identification of ABP-targets, the authors cut the gel at the position of ABP signaling and performed a mass spectrometry analysis. In their analysis why did the authors not try to identify the tryptic fragment that contains the active-site serine covalently attached to the ABP? In this way, the authors could identify other potential proteases that bind the ABP (therefore they are active in the sample).
3. In Figure 3C why does the inactive KLK13 sample show a signal?
4. What is the nature of inactive KLK13 (e.g. mutant at active site Ser?)

Is the work clearly and accurately presented and does it cite the current literature?

Yes

Is the study design appropriate and is the work technically sound?

Yes

Are sufficient details of methods and analysis provided to allow replication by others?

Partly

If applicable, is the statistical analysis and its interpretation appropriate?

Not applicable

Are all the source data underlying the results available to ensure full reproducibility?

Yes

Are the conclusions drawn adequately supported by the results?

Yes

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research